ArticleAntimicrobial agents and chemotherapy2006
In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 113 citations in OpenAlex.
- Mechanistic Insights into Human Defensin Antimicrobial Activity from Membrane Simulations.The Journal of membrane biology · 2026Article
- Combating Bacterial Infections with Vitamin D-Induced Antimicrobial Peptides.Advances in experimental medicine and biology · 2026Review
- Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Article
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Understanding the Roles of Host Defense Peptides in Immune Modulation: From Antimicrobial Action to Potential as Adjuvants.Journal of microbiology and biotechnology · 2023Review
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- Improving Fmoc Solid Phase Synthesis of Human Beta Defensin 3.International journal of molecular sciences · 2022Article
- The Remarkable Innate Resistance of Burkholderia bacteria to Cationic Antimicrobial Peptides: Insights into the Mechanism of AMP Resistance.The Journal of membrane biology · 2022Article
- Lipocalin-2 is an essential component of the innate immune response to Acinetobacter baumannii infection.PLoS pathogens · 2022Article
- Local Defence System in Healthy Lungs.Clinics and practice · 2021Article
- Coexistence ofFrontiers in cellular and infection microbiology · 2020Article
- BD-2 and BD-3 increase skin flap survival in a model of ischemia and Pseudomonas aeruginosa infection.Scientific reports · 2019Article
- 2-Hydroxylation ofInfection and immunity · 2019Article
- Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.Scientific reports · 2019Article
- Expression and antimicrobial character of cells transfected with human β‑defensin‑3 against periodontitis‑associated microbiota in vitro.Molecular medicine reports · 2017Article
- Perspectives for clinical use of engineered human host defense antimicrobial peptides.FEMS microbiology reviews · 2017Review
- β-Defensins in the Fight against Helicobacter pylori.Molecules (Basel, Switzerland) · 2017Review
- Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria.Drug design, development and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial activity of human beta-defensin 3 (hBD-3) against multidrug-resistant clinical isolates of Staphylococcus aureus, Enterococcus faecium, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii was evaluated. A fast bactericidal effect (within 20 min) against all bacterial strains tested was observed. The presence of 20% human serum abolished the bactericidal activity of hBD-3 against gram-negative strains and reduced the activity of the peptide against gram-positive strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.